Welcome to our dedicated page for Neurizon Therapeutics news (Ticker: NUZTF), a resource for investors and traders seeking the latest updates and insights on Neurizon Therapeutics stock.
Neurizon Therapeutics Limited (OTCQB: NUZTF; ASX: NUZ) is a clinical-stage biotechnology company focused on developing NUZ-001, an investigational treatment for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease. This news page aggregates company announcements and media releases that relate to its neurodegenerative disease programs and corporate developments.
According to Neurizon, its strategy is to accelerate access to effective ALS treatments while exploring the potential of NUZ-001 for broader neurodegenerative applications. News about the company often highlights progress in clinical development, participation in collaborative trial frameworks such as the HEALEY ALS Platform Trial, and steps it is taking toward late-stage development and regulatory preparation for NUZ-001.
Coverage also includes updates on Neurizon’s partnership with Elanco Animal Health, including the exclusive global license agreement for Monepantel, the active pharmaceutical ingredient in NUZ-001. Announcements may describe how this agreement supports regulatory foundations by providing access to animal safety data and manufacturing data, as well as governance developments such as the appointment of an Elanco-designated Board Observer.
Investors and observers can use this page to review Neurizon’s own descriptions of its clinical programs, licensing arrangements, and strategic collaborations in the neurodegeneration field. By following these updates, readers can track how the company presents its progress in advancing NUZ-001, its engagement in international collaborations, and its stated aim of creating new horizons for patients and families affected by complex neural disorders.
Neurizon Therapeutics (ASX: NUZ; OTCQB: NUZTF) has completed enrolment in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating its lead investigational therapy NUZ-001 in amyotrophic lateral sclerosis (ALS). The company reports that 250 participants were enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment within the HEALEY ALS Platform Trial to date.
According to Neurizon, completion of recruitment materially de-risks execution of its lead late-stage clinical program and allows anticipated topline efficacy and safety results for NUZ-001 to be brought forward to late Q2 CY2027, earlier than previously expected. Participants will now progress through a 36-week randomised controlled treatment period followed by a 36-week active treatment extension, with the company focused on disciplined trial execution across the HEALEY ALS Platform Trial network in the United States.
Neurizon (OTCQB: NUZTF) will expand Regimen I of the HEALEY ALS Platform Trial from 160 to 240 participants, comprising 180 NUZ-001 patients and 60 placebo controls. The larger cohort is designed to preserve statistical power, enable richer subgroup and biomarker analyses, and avoid reliance on placebo data from other regimens.
Driven by faster-than-expected enrolment and added philanthropic funding, Neurizon now anticipates last participant dosing in Q2 CY2027 and topline results in early Q3 CY2027, with no change to funding needs through completion and only a modest increase in total trial cost.
Neurizon Therapeutics announced on 26 November 2025 that Justine Conway, Global Head of Business Development at Elanco (NYSE: ELAN), has been appointed as an Elanco-designated Board Observer. The appointment follows an exclusive global license agreement for Monepantel (active ingredient in NUZ-001) dated 2 July 2025, and is intended to reinforce Neurizon's regulatory foundations by providing ongoing access to animal safety and manufacturing data needed for future trials and approvals.
Ms Conway brings more than 20 years of healthcare and animal health business development experience. As Board Observer she may attend and participate in board and committee meetings but will not hold voting rights. The company said her expertise will support advancement of NUZ-001 toward late-stage development and planned entry into the HEALEY ALS Platform Trial this quarter.